Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients.

Journal of Medical VirologyVolume 95, Issue 8 e29027 LETTER TO THE EDITOR Role of tixagevimab-cilgavimab in preventing SARS-CoV-2 in hematopoietic stem cell transplant and chimeric antigen receptor T-cell therapy recipients Aswani Thurlapati, Corresponding Author Aswani Thurlapati [email protected] orcid.org/0000-0001-9618-2563 Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA Correspondence Aswani Thurlapati, Department of Hematology & Oncology, Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St, Suite 219, Charleston, SC, 29429, USA. Email: [email protected]Search for more papers by this authorMary McGann, Mary McGann Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorJames A. Davis, James A. Davis orcid.org/0000-0001-7978-1652 Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorKatelynn Granger, Katelynn Granger Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorKiera Roubal, Kiera Roubal Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorDeidra Smith, Deidra Smith Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorKelly J. Gaffney, Kelly J. Gaffney Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorAlyssa Cendagorta, Alyssa Cendagorta Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorAmanda Herbst, Amanda Herbst Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorLindsey Hendrickson, Lindsey Hendrickson Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorBrian T. Hess, Brian T. Hess Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorHamza Hashmi, Hamza Hashmi Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this author Aswani Thurlapati, Corresponding Author Aswani Thurlapati [email protected] orcid.org/0000-0001-9618-2563 Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA Correspondence Aswani Thurlapati, Department of Hematology & Oncology, Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas St, Suite 219, Charleston, SC, 29429, USA. Email: [email protected]Search for more papers by this authorMary McGann, Mary McGann Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorJames A. Davis, James A. Davis orcid.org/0000-0001-7978-1652 Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorKatelynn Granger, Katelynn Granger Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorKiera Roubal, Kiera Roubal Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorDeidra Smith, Deidra Smith Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorKelly J. Gaffney, Kelly J. Gaffney Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorAlyssa Cendagorta, Alyssa Cendagorta Department of Pharmacy, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorAmanda Herbst, Amanda Herbst Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorLindsey Hendrickson, Lindsey Hendrickson Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorBrian T. Hess, Brian T. Hess Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this authorHamza Hashmi, Hamza Hashmi Department of Hematology and Bone Marrow Transplant, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USASearch for more papers by this author First published: 07 August 2023 https://doi.org/10.1002/jmv.29027Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 American Society of Hematology. ASH-ASTCT Covid-19 vaccination for HCT and car T cell recipients: Frequently asked questions. ASH-ASTCT COVID-19 Vaccination for HCT and CAR T cell recipients. Hematology.org. (n.d.) Accessed January 25, 2023. https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients 2Grivas P, Khaki AR, Wise-Draper TM, et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021; 32(6): 787-800. doi:10.1016/j.annonc.2021.02.024 3Atanackovic D, Luetkens T, Avila SV, et al. Anti-SARS-CoV-2 immune responses in patients receiving an allogeneic stem cell or organ transplant. Vaccines. 2021; 9(7):737. doi:10.3390/vaccines9070737 4Levin MJ, Ustianowski A, De Wit S, et al, PROVENT Study Group. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022; 386(23): 2188-2200. doi:10.1056/NEJMoa2116620 5Feng S, Phillips DJ, White T, et al, Oxford COVID Vaccine Trial Group. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Med. 2021; 27(11): 2032-2040. doi:10.1038/s41591-021-01540-1 6Soeroto AY, Yanto TA, Kurniawan A, Hariyanto TI. Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2023; 33(2):e2420. doi:10.1002/rmv.2420 7Jondreville L, D'Aveni M, Labussière-Wallet H, et al. Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the omicron wave: a multicentric retrospective study of SFGM-TC. J Hematol Oncol. 2022; 15(1): 169. doi:10.1186/s13045-022-01387-0 8Kertes J, Shapiro Ben David S, Engel-Zohar N, et al. Association between AZD7442 (tixagevimab-cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality. Clin Infect Dis. 2023; 76(3): e126-e132. doi:10.1093/cid/ciac625 9 Centers for Disease Control and Prevention. CDC Covid Data Tracker. (n.d.) Accessed January 25, 2023. https://covid.cdc.gov/covid-data-tracker/#variant-proportions Volume95, Issue8August 2023e29027 ReferencesRelatedInformation